Conflict of interest Dr Hendriks and Dr van de Kerkhof participated in a trial funded by Basilea Pharmaceutica. Dr de Jong served as consultant for and participated in research with Biogen, Serono, Wyeth and Abbott. Dr Seyger has served as a consultant for Wyeth, Pfizer and Abbott and received grants from Pfizer and LEO Pharma. Dr van de Kerkhof served as consultant for Schering Plough, Cellgene, Centocor, Allmirall, UCB, Wyeth, Pfizer, Soffinova, Abbott, Actelion, Galderma, Novartis, Janssen Cilag and LEO Pharma. He also received research grants form Centocor, Wyeth, Schering Plough, Merck Serono, Abbott, Philips Lighting, Pfizer, Janssen Cilag and LEO Pharma.
Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review
Article first published online: 20 DEC 2012
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 8, pages 931–951, August 2013
How to Cite
Hendriks, A.G.M., Keijsers, R.R.M.C., de Jong, E.M.G.J., Seyger, M.M.B. and van de Kerkhof, P.C.M. (2013), Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology, 27: 931–951. doi: 10.1111/jdv.12058
Funding sources This systematic review was funded by Leo Pharma. LEO Pharma played no role in the design and conduct of the study or in the data collection, data management, data analysis, interpretation of the data, manuscript preparation, manuscript review or manuscript approval.
- Issue published online: 17 JUL 2013
- Article first published online: 20 DEC 2012
- Received: 7 August 2012; Accepted: 29 October 2012
Background Most psoriasis patients suffering from mild to moderate disease are treated with first-line topical treatments, including corticosteroids, vitamin D analogues, topical retinoids and calcineurin inhibitors. Although evidence-based guidelines on combinations are lacking, the majority of patients will be treated with combinations of these popular topicals at some point during their life-long treatment.
Objectives We intended to systematically review all available literature on the efficacy and safety of combinations of first-line topicals in chronic plaque psoriasis, and ultimately, to propose recommendations for combined regimens concerning first-line treatments.
Methods Databases used as data sources were PubMed, EMBASE and the Cochrane Controlled Clinical Trial Register. According to standardized procedures, literature searches were performed and a level of evidence was determined.
Results In total, 2918 publications on topical combination therapy were revealed, of which 45 articles on first-line combinations were included. The combination of potent and superpotent corticosteroids with vitamin D analogues provides an improvement of psoriasis within 2 weeks, reaching a maximal improvement after 4 weeks in the majority of patients. The two-compound product permits once-daily treatment and therefore is a good solution for chronic plaque psoriasis including scalp psoriasis. Combinations of corticosteroids, with tazarotene or with calcineurin inhibitors do not provide an advantage above corticosteroid monotherapy.
Conclusion The combination of potent corticosteroids with calcipotriol has been studied most extensively and should be regarded as an efficacious and safe treatment option with the two-compound products as the most practical solution.